In life sciences, making the right decision means connecting clinical research, competitive intelligence and market signals before the picture changes.
In this episode of The Beat's AI at HLTH series, host Sandy Vance talks with Sina Falaki, the Senior Director of Solution Marketing at AlphaSense, about how AI is transforming research and strategic decision-making in pharma and biotech.
They explore AI-powered competitive intelligence, drug pipeline monitoring, evidence-backed analysis and always-on research agents. Sina also explains why human expertise remains essential and how life sciences teams can turn fragmented information into actionable intelligence that stays current.
In this episode, they talk about:
Why research capacity can become a strategic bottleneck for pharmaceutical and biotech companies
How AI connects clinical trial data, financial research, expert insights and internal knowledge
Why missing or misinterpreting a market signal can affect licensing and portfolio decisions
How AlphaSense's Super Analyst supports ongoing competitive intelligence and pipeline monitoring
Why clinical evidence, management forecasts and expert opinions shouldn't carry equal weight
How source citations and transparency support more trustworthy AI-assisted analysis
Why AI can help researchers spend less time gathering information and more time challenging assumptions
How to evaluate an AI research workflow over a 90-day pilot
A Little About Sina:
Sina Falaki is Senior Director of Solution Marketing at AlphaSense, where he leads go-to-market strategy for life sciences and other corporate markets. With experience bringing technology solutions to market at IBM, Procore and Motive, he works closely with strategy, competitive intelligence and finance leaders to help organizations apply AI-powered market intelligence to complex business decisions, including drug development, portfolio strategy and commercialization.
